RGD modified albumin nanospheres for tumour vasculature targeting

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 1, 2011, Pages 33-40

  Dubey, Praveen K ^a   Singodia, Deepak ^b   Verma, Rahul K ^b   Vyas, Suresh P ^c  

^a Strides Arcolab Limited   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c DR H S GOUR UNIVERSITY   (India)

Author keywords

albumin nanospheres; angiogenesis; cancer chemotherapeutics; cyclic RGD peptide; tumour targeting

Indexed keywords

ALBUMIN; ARGINYLALANYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; FLUOROURACIL; NANOSPHERE; TRIPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUGATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; DRUG TUMOR LEVEL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; MOLECULAR STABILITY; MOUSE; NONHUMAN; PARTICLE SIZE; STEREOSPECIFICITY; TUMOR VASCULARIZATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CATTLE; CELLS, CULTURED; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; FLUOROURACIL; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NANOSPHERES; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PARTICLE SIZE; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; SERUM ALBUMIN, BOVINE; TISSUE DISTRIBUTION; UMBILICAL VEINS;

EID: 78650408680     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01180.x     Document Type: Article

References (37)

1. Kreuter J,. Nanoparticles and microparticles for drug and vaccine delivery. J Anat 1996; 189: 503-505. (Pubitemid 27011002)
2. Tan ML, et al. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol 2009; 61: 3-12.
3. Zonghua L, et al. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev 2008; 60: 1650-1662.
4. Lee T, et al. Serum albumin beads: an injectable biodegradable system for the sustained release of drugs. Science 1981; 213: 233-235.
5. Heidrun W, et al. Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles. J Control Release 2004; 96: 483-495.
6. Feng-Qian L, et al. Mannose 6-phosphate-modified bovine serum albumin nanoparticles for controlled and targeted delivery of sodium ferulate for treatment of hepatic fibrosis. J Pharm Pharmacol 2009; 61: 1155-1161.
7. Thakkar H, et al. Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS PharmSciTech 2005; 06: E65-E73.
8. Wartlicka H, et al. Tumour cell delivery of antisense oligonucleotides by human serum albumin next term nanoparticles. J Control Rel 2004; 96: 483-495.
9. Tomilson E, Burger JJ,. Methods in enzymology. In:, Widder K, Green R, eds. Drug and Enzyme Targeting. Vol. 112. London: Academic Press, 1995: 27.
10. Shena ZY, et al. Preparation and characterization of thermo-responsive albumin nanospheres. Int J Pharmaceutics 2008; 346: 133-114.
11. Zips D, et al. Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. J Pharm Pharmacol 2008; 60: 1019-1028.
12. Forssen E, Willis W,. Ligand targeted liposomes. Adv Drug Deliv Rev 1998; 29: 249-271.
13. Arap W, et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-380.
14. Ellerby HM, et al. Anticancer activity of targeted pro-apoptotic peptides. Natl Med 1999; 5: 1032-1038.
15. Schiffelers RM, et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 2003; 91: 115-122.
16. Bertolini F, et al. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov Today 2007; 12: 806-812.
17. Shannon AM, Williams KJ,. Antiangiogenics and radiotherapy. J Pharm Pharmacol 2008; 60: 1029-1036.
18. Brooks PC, et al. Requirement of vascular integrin avb3 for angiogenesis. Science 1994; 264: 569-571.
19. Friedlander M, et al. Definition of two angiogenic pathways by distinct integrins. Science 1995; 270: 1500-1502.
20. Kumar CC, et al. Targeting integrins alpha v beta3 and alpha v beta 5 for blocking tumor-induced angiogenesis. Adv Exp Med Biol 2000; 476: 169-180.
21. Hynes RO,. A reevaluation of integrins as regulators of angiogenesis. Natl Med 2002; 8: 918-921.
22. Bibby DC, et al. Surface Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int J Pharmaceutics 2005; 293: 281-290.
23. Danhier F, et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. J Control Release 2009; 140: 166-173.
24. Cressman S, et al. Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells. Bioconjug Chem 2009; 20: 1404-1411.
25. McCusker FC, et al. Solid-phase synthesis of cRGDfK. Derivatives: on-resin cyclisation and lysine functionalisation. Bioorg Med Chem Lett 2002; 12: 547-549.
26. Miron T, Wilchek M,. A simplified method for the preparation of succinimidyl carbonate polyethylene glycol for coupling to proteins. Bioconjug Chem 1993; 4: 568-569.
27. Jaffe EA, et al. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-2756.
28. Compagnon P, et al. Simple high-performance liquid chromatographic method for the quantitation of 5-fluorouracil in human plasma. J Chromatogr 1996; 677: 380-383.
29. Kreisle RA, Ershler WB,. Investigation of tumor angiogenesis in an id mouse model: role of host tumor interaction. J Natl Cancer Inst 1988; 80: 845-849.
30. Gladson CL, Cheresh DA,. Glioblstoma expression of vitronectin and the avb3 integrin. J Clin Invest 1991; 88: 1924-1932.
31. Kok RJ, et al. Preparation and functional evaluation of RGD-modified proteins as avb3 integrin directed therapeutics. Bioconjug Chem 2002; 13: 128-135.
32. Gao Y, et al. Synthesis of vascular endothelial cells-targeting nanometer gene drug carrier Tyr-KGD-PEG-PEI and its biological activity. Yaoxue Xuebao 2009; 44: 1034-1039.
33. Li Z, et al. RGD-Conjugated dendrimer-modified gold nanorods for in vivo tumor targeting and photothermal therapy. Mol Pharm 2010; 7: 94-104.
34. Fidler I,. Selection of successive tumor lines for metastasis. Natl New Biol 1973; 242: 148-149.
35. Fidler IJ,. The Ernst W. Bertner memorial award lecture: the evolution of biological heterogeneity in metastatic neoplasms. In:, Nicolson GI, Milas I, eds. Cancer Invasion and Metastasis. Biologic and Therapeutic Aspects. New York: Rason Press, 1984: 5-9.
36. Boehm T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
37. Streit M, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 1999; 96: 14888-14893.